Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache
- First Online:
- 68 Downloads
Tension-type headache (TH) is a common condition, the pathophysiology of which remains undetermined. Evidence implicates sustained contraction of pericranial muscles to be a major cause. A recent preliminary study demonstrated the effectiveness of botulinum toxin type A (BTX-A) in patients suffering from chronic TH. To further investigate this, we performed a study to compare the efficacy of BTXA with the steroid methylprednisolone (both administered with the local anesthetic lidocaine), when administered by injection into the tender points of cranial muscles in patients with TH.
A significant decrease in the median pain score (assessed using a standard visual analogue scale [VAS]) was observed at 60 days post injection of BTX-A compared with the pain score achieved following steroid therapy. All patients treated with BTX-A experienced a gradual decrease in median pain severity scores at 30 days and 60 days post treatment. The beneficial effects of BTX-A therapy continued to improve 60 days following injection, whereas the effects of steroid therapy at this time point began to decline. This study clearly demonstrates the effectiveness of BTX-A for the treatment of TH.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Rasmussen BK: Epidemiology. In The Headaches. Edited by Olesen J et al. New York: Raven Press; 1993:439–443.Google Scholar
- 3.Schoenen J: Tension-type headache: differential diagnosis. In The Headaches. Edited by Olesen J et al. New York: Raven Press; 1993:509–510.Google Scholar
- 4.Bogduk N: Anatomy and pathology. In The Headaches. Olesen J et al. New York: Raven Press; 1993:445–454.Google Scholar
- 8.Olesen J, Schoenen J: Synthesis. In The Headaches. Edited by Olesen J et al. New York: Raven Press; 1993:493–496.Google Scholar
- 9.Olesen J, Langemark M: Mechanisms of tension headache: a speculative hypothesis. In Basic Mechanisms of Headache. Edited by Olesen J, Edvinsson L. Amsterdam: Elsevier; 1988:457–461.Google Scholar
- 11.Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8(suppl 7):1–96.Google Scholar
- 16.Merskey H, Bogduk N: Classification of Chronic Pain, edn 2. Seattle: IASP Press; 1994.Google Scholar
- 18.Simons DG, Mense S: Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 1998, 75:1–17. Explains the importance of measuring muscle tone in clinical conditions of pain associated with muscle spasm. Clinical conditions associated with painful muscle spasm include TH and spasmodic torticollis.CrossRefPubMedGoogle Scholar
- 20.Jensen K, Jensen R: Myogenic nociception and pain thresholds. In The Headaches. Edited by Olesen J et al. New York: Raven Press; 1993:227–231.Google Scholar
- 21.Jensen R, Schoenen J: Pain thresholds. In The Headaches. Edited by Olesen J et al. New York: Raven Press; 1993:483–487.Google Scholar
- 23.Holroyd K: Behavioural treatment strategies. In Tension-Type Headache: Classification, Mechanisms and Treatment. Edited by Olesen J, Schoenen J. New York: Raven Press; 1993:245–254.Google Scholar
- 26.Porta M, Perretti A, Gamba M, et al.: Compartment botulinum toxin injection for myofascial pain relief [abstract]. DOLOR 1997, 12(suppl 1):42. Reports the beneficial effects of compartmental injection of botulinum toxin type A in the treatment of myofascial pain syndrome.Google Scholar
- 27.Yue SK: Initial experience in the use of botulinum toxin A for the treatment of myofascial related muscle dysfunctions. J Musculoskeletal Pain 1995, 3(suppl 1):22.Google Scholar
- 29.Schurch B, Hauri D, Rodic B, et al.: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996, 155:1023–1029. The muscle relaxing properties of botulinum toxin type A are used, in this study, to correct detrusor-sphincter dyssynergia in 24 patients with spinal cord injury. The effects of botulinum toxin type A were reported to last for 3 to 9 months.CrossRefPubMedGoogle Scholar
- 30.Relja M: Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997, 4(suppl 2):S71-S73. Demonstrates the effectiveness of botulinum toxin type A in the treatment of TH. All 10 patients showed a significant decrease in tenderness scores of the frontalis, trapezius, and sternocleidomastoideus muscles 1 to 2 weeks post injection and clinical improvement lasted up to 8 weeks.Google Scholar
- 31.Wheeler AH: Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998, 38:468–471. Discusses the role of pericranial muscle tension in refractory headaches. Reduction of pericranial muscle tension by injection of botulinum toxin type A may be useful for reducing primary myalgia and secondary headache.CrossRefPubMedGoogle Scholar
- 34.Kudrow L: Muscle contraction headache. In Handbook of Clinical Neurology. Edited by Vinken PJ, Bruyn GW. Amsterdam: North Holland Publishing Company; 1986:343–352.Google Scholar